Cancer treatment
Scientists in the United States have reported new findings in the field of cancer research, revealing that nonspecific immunotherapy using intratumoral lipopolysaccharide and zymosan A, but not GM-CSF, is effective in generating an anti-tumor response in subcutaneous RG-2 gliomas. This treatment approach may be useful in generating an anti-tumor response
Cancer treatment
Scientists at the M.D. Anderson Cancer Center have successfully combined targeted therapy with radiation treatment to enhance the therapeutic efficacy of lung cancer treatment. Researchers evaluated the feasibility of using ZD6474, a small-molecule inhibitor of VEGFR2 and EGFR tyrosine kinases, in conjunction with radiation therapy in an orthotopic model
Cancer research
In a groundbreaking study, researchers from the University of Bergen discovered that normal brain cells can contribute to the bystander effect in suicide gene therapy of malignant glioma. The study, published in Clinical Cancer Research, revealed that lentiviral vectors pseudotyped with glycoproteins of the lymphocytic choriomeningitis virus (LCMV-GP) can effectively
Cancer research
Epigenetic-modifying agents, specifically sodium butyrate and decitabine (5-Aza-dC), have shown promise in increasing iodine uptake in thyroid carcinoma cells, potentially leading to more effective treatment options for radioablation-resistant thyroid cancer. Researchers at the University of Iowa, led by M.J. Provenzano, conducted a study to investigate the effect of these
Cancer treatment
Leading cancer charities in Britain have been accused of taking part in a trip to Europe, funded by a major drugs company, Sanofi Aventis. The trip, described as an "educational" and "parliamentary and stakeholder working group" meeting, is designed to showcase new cancer drugs and treatments.
Cancer treatment
Recent studies have shed light on potential new approaches to cancer treatment, focusing on synergy between established therapies and targeted interventions. Research from the United States and the Netherlands has demonstrated the effectiveness of combining anticancer drugs with targeted agents to enhance treatment outcomes. Three studies have been particularly notable,
Cancer treatment
Research from Introgen Therapeutic Inc. has shown that the MDA-7 gene transfer can enhance the sensitivity of breast carcinoma cells to chemotherapy and radiation. The study found that cells expressing MDA-7 displayed additive or synergistic cytotoxicity and apoptosis when treated with conventional anticancer drugs or radiation. In vivo, animals treated
Cancer treatment
Scientists at Yale University have successfully used short interfering RNA (siRNA) to inhibit the expression of vascular endothelial growth factor (VEGF) A in human colon cancer cells, resulting in a significant decrease in cellular proliferation. Researchers hypothesized that VEGF inhibition would impede the growth of colon cancer cells, and their
Cancer treatment
MedImmune, Inc., a global biotechnology company, has sponsored an American Association for Cancer Research (AACR) fellowship to support the development of biologics-based cancer therapies. The recipient of the $40,000 research fellowship, Robert R. Jenq, MD, of the Memorial Sloan-Kettering Cancer Center in New York, is evaluating several techniques to
Cancer treatment
The European Commission has granted marketing authorization to extend the use of Erbitux (Cetuximab) in combination with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck. This development marks a significant advancement for patients with head and neck cancer, with Erbitux being the first and
Cancer treatment
A team of German researchers from the Deutsch Krebsforschungszentrum (German Cancer Research Center) has made a significant breakthrough in the field of cancer therapy. The study, published in Cancer Research, has revealed that cancer cell DNA methyltransferase inhibitors display functional diversity. This discovery has the potential to revolutionize cancer treatment,
Cancer treatment
A recent study from the University of Ghent in Belgium provides essential information for policymakers considering reimbursement for Herceptin in breast cancer therapy. The study conducted a cost-effectiveness analysis of Herceptin, a humanized monoclonal antibody, in the adjuvant setting for breast cancer. Researchers calculated treatment costs and life expectancy data
